Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

Eli Lilly (LLY) stock dropped by 0.22%, underperforming the S&P 500’s 0.49% gain. Over the past month, the stock has fallen 4 ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look ...

Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...

Stock futures are little changed Wednesday night after the major averages rebounded on hopes for concessions on President ...

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Back in December, I argued why I was ready to upgrade the stock of the embattled weight loss drugs leader Eli Lilly and Company (NYSE:LLY) even as it fell into a bear market after peaking in August.